Company intelligence / Profile preview
Mabworks Biotech
Beijing, Beijing, China
- Ownership
- Public · 810235
- Development stage
- Phase 3
01
Overview
Mabworks has advanced a differentiated pipeline with several clinical-stage assets. Its core product MIL62—a novel third-generation anti-CD20 antibody—has completed recruitment for Phase III trials in PMN and FL, with additional studies ongoing in SLE and NMOSD. Other programs include bispecific T-cell engagers for hematological malignancies/autoimmune disease, multi-specifics for multiple myeloma, as well as candidates targeting PCSK9, Claudin18.2, LAG3, CD40. The company’s technologies have been validated through strategic partnerships with global pharma companies.
- Therapeutic areas
- NephrologyOncologyImmunologyCardiovascularNeurology
- Modalities
- Monoclonal antibodies (mAbs)Bispecific antibodies (including T-cell engagers)Antibody drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →03
Partnerships
Beyond the preview
Go deeper on Mabworks Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mabworks Biotech.